ArticleBlood cancer discovery2021
Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors.
Open access · greenAbstract read
In one paragraph
Article in Blood cancer discovery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers.
0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed
6.7field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 97 citations in OpenAlex.
- Preclinical Development of Tuspetinib for the Treatment of Acute Myeloid Leukemia.Cancer research communications · 2025Trial
- Quizartinib Resistance Mutations and Treatment Outcomes in Relapsed or Refractory FLT3-ITD-Positive AML.Cancer science · 2026Article
- Sphingosine-1-phosphate receptor modulators resensitize FLT3-ITD acute myeloid leukemia cells with NRAS mutations to FLT3 inhibitors.Leukemia · 2026Article
- Clinical implications of RAS mutations in AML: prognostic significance is based upon the involved gene and mutation complexity.Blood advances · 2026Article
- Article
- An unprecedented potent inhibitor of MV4-11 cells: investigations into the mechanism of action beyond FLT3 inhibition.Bioorganic chemistry · 2026Article
- New selective and allosteric FLT3 inhibitors show efficacy against resistant acute myeloid leukemia cells.iScience · 2026Article
- Outcomes of relapsed or refractory acute myeloid leukemia after menin inhibition failure.Blood advances · 2026Article
- Article
- Article
- Optimizing lower intensity triplet therapy in acute myeloid leukemia: a practical guide.Blood cancer journal · 2025Review
- Sitravatinib combined with venetoclax exerts effective synergy to eliminate acute myeloid leukemia cells with FLT3-ITD mutations.Translational oncology · 2025Article
- SIMPLE: A One-Pot RPA-Cas12b Method for Single Nucleotide Variations Identification with an Expanded Scope and Clinical Applications.Phenomics (Cham, Switzerland) · 2025Article
- Multi-selective RAS(ON) Inhibition Targets Oncogenic RAS Mutations and Overcomes RAS/MAPK-Mediated Resistance to FLT3 and BCL2 Inhibitors in Acute Myeloid Leukemia.bioRxiv : the preprint server for biology · 2025Article
- Review
- Advances and Challenges in Quizartinib-Based FLT3 Inhibition for Acute Myeloid Leukemia: Mechanisms of Resistance and Prospective Combination Therapies.European journal of haematology · 2025Review
- Precision Medicine in Myeloid Neoplasia: Challenges and Opportunities.Journal of personalized medicine · 2025Review
- Overcoming the sorafenib resistance mechanism in FLT3-mutated acute myeloid leukemia: molecular basis and new targets.Frontiers in oncology · 2025Review
- Quizartinib: a potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD-positive AML.Journal of hematology & oncology · 2024Review
- A Combinatorial Functional Precision Medicine Platform for Rapid Therapeutic Response Prediction in AML.Cancer medicine · 2024Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
27 authors at 2 institutions in 2 countries.
Ahmad S Alotaibi *The Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Musa Yilmaz *The Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Rashmi Kanagal-ShamannaThe Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Sanam LoghaviThe Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Tapan M KadiaThe Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Courtney D DiNardoThe Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Gautam BorthakurThe Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Marina KonoplevaThe Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Sherry A PierceThe Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Sa A WangThe Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Guilin TangThe Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Veronica GuerraThe Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Bachar SamraThe Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Naveen PemmarajuThe Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Elias JabbourThe Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Nicholas J ShortThe Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Ghayas C IssaThe Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Maro OhanianThe Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Guillermo Garcia-ManeroThe Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Kapil N BhallaThe Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Keyur P PatelThe Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Koichi TakahashiThe Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Michael AndreeffThe Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jorge E CortesGeorgia Cancer Center, Augusta University, Augusta, Georgia.
Hagop M KantarjianThe Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Farhad RavandiThe Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Naval DaverThe Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas. ndaver@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USAugusta University Health · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MUniversity of Texas M.D. Anderson Cancer SPORE-LeukemiaP50CA100632 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SHPALL, ELIZABETH J · 2003 to 2023
$43.7MBiology and novel therapy of AML expressing somatic or germline mutant RUNX1R01CA255721 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BHALLA, KAPIL, DINARDO, COURTNEY · 2021 to 2025
$2.4MNCI NIH HHS P30 CA016672NCI NIH HHS P50 CA100632NCI NIH HHS R01 CA255721
Abstract
Despite promising results with FLT3 inhibitors (FLT3i), response durations remain short. We studied pretreatment and relapse bone marrow samples from patients with
Indexed as
Drug Resistance, Neoplasmfms-Like Tyrosine Kinase 3Leukemia, Myeloid, AcuteHigh-Throughput Nucleotide SequencingHumansMutationProtein Kinase InhibitorsFLT3 protein, humanfms-Like Tyrosine Kinase 3Protein Kinase Inhibitorsemergent mutationsFLT3-inhibitor resistanceFLT3 mutated AMLType IType II
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.